Accelerating Your Pipeline with
Science and Speed
At Zyphar’s Biopharmaceuticals, we bring scientific rigor and operational agility to the development of niche Oncology APIs, advanced intermediates and key starting materials. Our end-to-end capabilities span route scouting, process optimization, analytical development, and regulatory documentation—empowering innovators to move confidently from concept to clinic.
With deep expertise across hazardous, moisture-sensitive, and cytotoxic chemistries, our dedicated process R&D teams engineer robust, scalable, and cost-effective synthesis pathways. Every step is underpinned by integrated process safety, data integrity, and global compliance, ensuring a smooth transition to GMP manufacturing and regulatory submissions.
Why International Companies Choose CDMO in India?
High-Quality Standards: Indian CDMOs operate in compliance with global regulatory frameworks and other international authorities, ensuring world-class product quality.
Featured Services
Route Scouting
Efficient identification of optimal synthetic routes using data and feasibility studies.
Process Development & Optimization
Risk-informed development, impurity profiling, and scalable optimization for cost and purity.
Analytical Development
Custom methods, impurity markers, validation, and stability-indicating assays.
Integrated Development Services
Early Phase Development
Lab-scale feasibility, synthetic optimization, and impurity identification.
Scale-Up Readiness
Execution of engineering and validation batches using advanced reactors and process tools.
Lifecycle Services
Rework/reprocessing studies, solvent recovery, impurity fate, and purge investigations.
Special Capabilities
Expertise in hazardous reactions, air-/moisture-sensitive chemistries, stereoselective synthesis, and more.
Why International Companies Choose CDMO in India?
India has emerged as a global hub for CDMO and contract manufacturing services due to its strong scientific ecosystem, regulatory maturity, and cost competitiveness. International pharmaceutical companies increasingly prefer CDMO services in India for the following reasons:
- High-Quality Standards: High-Quality Standards: Indian CDMOs operate in compliance with global regulatory frameworks and international authorities, ensuring world-class product quality.
- Cost Advantage: India offers significant cost efficiencies compared to US and European markets, without compromising on technology, compliance, or quality.
- Skilled Workforce: Access to a large pool of highly qualified scientists, chemists, and engineers with deep expertise in R&D and large-scale pharmaceutical manufacturing.
- Strong Regulatory Ecosystem: Multiple regulatory certified manufacturing facilities enable seamless access to regulated global markets.
- Integrated Capabilities: Leading Indian CDMOs like Zyphar’s Biopharmaceuticals provide end-to-end services from early development to commercial supply, including API intermediates and KSMs
Advantages of CDMO Services
Partnering with a trusted CDMO pharma company in India offers several strategic and operational advantages:
Accelerated Time-to-Market
Streamlined development and manufacturing processes help bring pharmaceutical products to market faster.
Scalability and Flexibility
Seamless transition from small clinical batches to large-scale commercial manufacturing.
Regulatory Expertise
Strong regulatory knowledge and compliance support help navigate complex approval requirements efficiently.
Innovation Support
Access to advanced technologies, specialized R&D infrastructure, and novel drug delivery platforms.
Risk Mitigation
Shared technical, regulatory, and manufacturing responsibilities reduce development and scale-up risks.
Cost Optimization
Outsourcing to a CDMO eliminates the need for heavy capital investment in in-house infrastructure.